NICE NG246 - Overweight and obesity management
Prescribe only as part of an overall plan for managing obesity in adults who have:
BMI of 28.0 kg/m2 or more with associated risk factors, or
BMI of 30.0 kg/m2 or more.
Continue treatment for longer than 3 months only if the person has lost at least 5% of their initial body weight since starting drug treatment
Continue for longer than 12 months only after discussing potential benefits and limitations with the patient.
Pack |
---|
42 capsule |
84 capsule |
120 capsule |
Pack |
---|
84 capsule |
Note variation in licensing of different brands of liraglutide
Saxenda brand is licensed for obesity indication
Recommended as an option for managing overweight and obesity alongside a reduced-calorie diet and increased physical activity in adults who meet the NICE criteria (TA664)
Primary care prescribers should NOT accept prescribing responsibility.
Prescribing must be initiated and maintained by a specialist multidisciplinary tier 3 weight management service.
Pack |
---|
5 pre-filled disposable injection |
Pack |
---|
5 pre-filled disposable injection |
3 pre-filled disposable injection |
Wegovy brand is licensed for obesity indication
Recommended as an option for managing overweight and obesity alongside a reduced-calorie diet and increased physical activity in adults who meet the NICE criteria (TA875)
Primary care prescribers should NOT accept prescribing responsibility.
Prescribing must be initiated and maintained by a specialist weight management service providing multidisciplinary management of overweight or obesity (including but not limited to tiers 3 and 4)
Pack |
---|
1 pre-filled disposable injection |
Pack |
---|
1 pre-filled disposable injection |
Pack |
---|
1 pre-filled disposable injection |
Pack |
---|
1 pre-filled disposable injection |
Pack |
---|
1 pre-filled disposable injection |